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Abstract
The mammalian tachykinins, substance P (SP) and hemokinin-1 (HK-1), are widely distributed throughout the nervous
system and/or peripheral organs, and function as neurotransmitters or chemical modulators by activating their cognate
receptor NK1. The TAC1 gene encoding SP is highly expressed in the nervous system, while the TAC4 gene encoding HK-1 is
uniformly expressed throughout the body, including a variety of peripheral immune cells. Since TAC4 mRNA is also
expressed in microglia, the resident immune cells in the central nervous system, HK-1 may be involved in the inflammatory
processes mediated by these cells. In the present study, we found that TAC4, rather than TAC1, was the predominant
tachykinin gene expressed in primary cultured microglia. TAC4 mRNA expression was upregulated in the microglia upon
their activation by lipopolysaccharide, a well-characterized Toll-like receptor 4 agonist, while TAC1 mRNA expression was
downregulated. Furthermore, both nuclear factor-kB and p38 mitogen-activated protein kinase intracellular signaling
pathways were required for the upregulation of TAC4 mRNA expression, but not for the downregulation of TAC1 mRNA
expression. These findings suggest that HK-1, rather than SP, plays dominant roles in the pathological conditions associated
with microglial activation, such as neurodegenerative and neuroinflammatory disorders.
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Introduction
Mammalian tachykinins comprise a family of neuropeptides
with a common carboxyl terminal amide motif. The representative
tachykinin peptide, substance P (SP), is encoded by the TAC1
gene and preferentially activates a G-protein-coupled receptor,
NK1. The most recently identified tachykinin member, hemoki-
nin-1 (HK-1; encoded by the TAC4 gene), also activates the NK1
receptor with similar affinity and potency to SP [1,2], although the
effects of SP and HK-1 are slightly different [3–6]. In addition, the
TAC4 and TAC1 expression patterns differ considerably. TAC1 is
highly expressed in the nervous system, while TAC4 is uniformly
expressed throughout the body [7]. TAC4 is expressed in a variety
of peripheral immune cells, including lymphocytes, monocytes and
macrophages [8–10]. Accordingly, HK-1 is involved in immune
functions and inflammation [2,5,11–14]. However, its role in the
nervous system remains almost unknown.
Microglia, the resident immune cells in the central nervous
system (CNS), also express the TAC4 gene [10,15], similar to the
case for peripheral immune cells. Microglia have significant roles
in various neurological diseases, such as neurodegenerative
disorders and chronic pain [16,17]. In these situations, microglia
become activated to upregulate and release a variety of
inflammatory mediators that contribute to the pathophysiology.
Therefore, HK-1 expression in microglia may also be involved in
the inflammatory processes mediated by these cells in the CNS. In
fact, we previously observed that the TAC4 expression level was
increased in the dorsal spinal cord in the neuropathic pain state, in
which activated microglia underlie the hyperalgesia. The increase
in TAC4 expression was suppressed by inhibiting microglial
activation [15]. However, it remains unknown how the tachykinin
genes are precisely regulated in microglia.
In this study, we examined the expression levels of the TAC1
and TAC4 tachykinin genes in microglia activated by lipopoly-
saccharide (LPS), a well-characterized Toll-like receptor 4 (TLR4)
agonist. TLR4 is a member of the pattern recognition receptors
that mediate innate immunity and induces microglial activation in
response to pathogen-derived and endogenous molecules. Upon
activation by LPS, TAC4 expression was significantly increased in
microglia, while TAC1 expression was decreased. Since TLR4-
induced activation of microglia results in the release of
inflammatory substances and mediates various CNS diseases
through multiple intracellular mechanisms [18], we further
examined the signaling pathways responsible for the regulation
of tachykinin expressions and found that the increase in TAC4
expression was mediated by nuclear factor (NF)-kB and p38
mitogen-activated protein kinase (MAPK).
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Ethics Statement
All experimental procedures were approved by the Nippon
Medical School Animal Care and Use Committee (approval
number: 22-054).
Materials
LPS (from Escherichia coli, serotype 0111:B4), Eagle’s minimal
essential medium and hemokinin peptide were obtained from
Sigma-Aldrich (St. Louis, MO). 4-(4-Fluorophenyl)-2-(4-methyl-
sulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB 203580) and SC-
514 were purchased from Merck (Darmstadt, Germany). Recom-
binant rat interleukin (IL)-1b was from R&D Systems (Minneap-
olis, MN). A rabbit anti-ionized calcium-binding adaptor molecule
1 (Iba I) antibody was from Wako (Osaka, Japan). Fetal calf serum
and an Alexa Fluor 488-conjugated donkey anti-rabbit IgG
antibody were from Life Technologies (Carlsbad, CA). VECTA-
SHIELD Mounting Medium with DAPI was from Vector
Laboratories (Burlingame, CA).
Primary microglial culture
Isolated primary microglial cultures were prepared as described
previously [19]. Briefly, primary mixed glial cell cultures from
whole brains of Sprague-Dawley rats at postnatal day 0–1 were
prepared in 75-cm
2 culture flasks and maintained in Eagle’s
modified essential medium containing 10% fetal bovine serum,
5 mg/ml of bovine insulin and 2% glucose at 37uCi n5 %C O 2.
After 2 weeks, the culture flasks were shaken on an orbital shaker
at 120 rpm at 37uC for 2 h and the medium was harvested.
Subsequently, microglia were recovered as adherent cells to
uncoated plastic dishes (Falcon 1001; Becton-Dickinson Japan,
Tokyo, Japan). The adherent microglia were collected with a
rubber policeman and plated at a concentration of 5610
6 cells per
6-cm plastic dish (Falcon 3002; Becton-Dickinson Japan). The
purity of the enriched microglia was more than 97%, as
determined by Iba I immunocytochemical staining.
Drug treatment of microglia
At 1 day after plating, the microglia were treated with LPS
(0.1 mg/ml), IL-1b (20 mg/ml), ATP (100 mM) or HK-1 (1 mM) for
24 h. To block the intracellular signaling pathways, the microglia
were treated with 30 mM SC-514, an NF-kB activation inhibitor,
or 10 mM of SB 203580, a p38 MAPK inhibitor, dissolved in
dimethyl sulfoxide at 1 h prior to LPS stimulation. Images of the
microglial morphology were captured using a high-resolution
digital camera equipped with a computer (Olympus, Tokyo,
Japan).
RNA isolation and quantitative PCR
Quantitative analyses of the rat TAC4, TAC1 and tachykinin
receptor (NK1,N K 2 and NK3) mRNA levels were performed as
previously described [15]. Total RNA was isolated using RNAiso
Plus (Takara, Shiga, Japan) according to the manufacturer’s
recommended protocol. First-strand cDNAs were synthesized using
0.3 mg of total RNA with oligo (dT)20 primer and an iScript Select
cDNA Synthesis Kit (Bio-Rad Laboratories, Tokyo, Japan). For
quantitative PCR, 0.75 ml of the first-strand cDNA was added to
14.25 ml of a reaction mixture containing TaqMan Gene Expression
Master Mix, 900 nMof eachprimer and 250 nM of TaqMan probe
and amplified using a Step One Plus Real-Time PCR System (Life
Technologies). PCR primers specific for rat TAC4, TAC1, NK1,
NK2, and NK3 were designed based on the cDNA sequences
deposited in GenBank (AY471575, NM_012666, NM_012667,
NM_080768 and NM_017053, respectively) using Primer Express
Version 2.0 (Life Technologies). The forward primers, reverse
primers and probes were 59-AGGGCTCGATAAAGGAGTTA-39,
59-TTCAGCCCTCTACCCAGCAT-39 and 59-TAGGCAGCT-
TCCTCAGC-39 for TAC4, 59-CGCAATGCAGAACTACGA-
AAGA-39,5 9-CGCGGACACAGATGGAGAT-39 and 59-CGT-
AAATAAACCCTGTAACGCACTATCTAT-39 for TAC1, 59-
CACCCGATACCTCCAGACACA-39,5 9-GGAGCCGTTGGA-
GGTGAGA-39 and 59-CAGCGTGTACAAGGTCAGCCGCCT-
39 for NK1,5 9-CTCCACAATGTACAACCCTATCATTTAT-39,
59-GAAAGCAAGCCGGAATCCA-39 and 59-CTGCCTTAAC-
CACAGGTTTCGCT-39 for NK2 and 59-CAACTACTGCC-
GCTTCCAGAA-39,5 9-GTCCACTGCAATGGCTGTCATA-39
and 59-TTCTTTCCCATCACAGCGGTGTTTGC-39 for NK3,
respectively. For quantification, the cDNA sequences of TAC4,
TAC1, NK1,N K 2 and NK3 were inserted into the pBluescript II
SK(+) vector (Agilent Technologies, Santa Clara, CA), pcDNA3
vector (Life Technologies) or the pGEM-T easy vector (Promega,
Madison, WI). The plasmids were then serially diluted to
concentrations of 1.0610
2–1.0610
5 mol per reaction tube for use
as standards. All PCR amplifications using the standards and
samples were performed intriplicate at 50uC for 2 min and 95uCf o r
10 min, followed by 40 cycles of 95uC for 15 s and 60uCf o r1m i n .
The number of cDNA copies was calculated using a standard curve
obtained from the set of control plasmids in each assay.
Immunocytochemical staining of Iba I
Microglia were seeded onto culture slides and allowed to
equilibrate for 24 h. The culture medium was removed and the
cells were washed in phosphate-buffered saline (PBS; pH 7.2) and
fixed with 4% paraformaldehyde for 15 min at room tempera-
ture. After two rinses in PBS, the cells were incubated in the
presence of 0.2% Triton X-100 for 10 min, rinsed with PBS
twice, blocked with 2% donkey serum for 30 min and incubated
with a primary rabbit antibody against Iba I (1:2000 dilution) at
4uC overnight. After three washes in PBS, the cells were
incubated with an anti-rabbit IgG antibody conjugated with
Alexa Fluor 488 (1:1000 dilution) at room temperature for 1 h.
To identify the stained and unstained cells, the slides were
mounted in VECTASHIELD Mounting Medium with DAPI,
and images were captured using a high-resolution digital camera
equipped with a computer (Olympus).
Statistical analysis
Values are presented as means 6 SEM. Differences in the
mRNA expression levels were analyzed by an unpaired t-test or
one-way repeated-measures ANOVA followed by individual post
hoc multiple comparisons (Dunnett’s test or Tukey–Kramer
multiple comparison test). Values of P,0.05 were considered to
indicate statistical significance.
Results
Changes in TAC4, TAC1 and tachykinin receptor mRNA
expressions in microglia following LPS treatment
In non-stimulated control microglia, the numbers of TAC4 and
TAC1 mRNA molecules were 8.6610
467.2610
3 (n=5) and
4.5610
367.6610
2 (n=7) molecules/mg total RNA, respectively
(Fig. 1A). In addition, the mRNA expression levels of NK1, as the
receptor for HK-1 and SP, and NK3 were 7.7610
369.2610
2 and
1.1610
464.2610
3 mol/mg total RNA, while NK2 mRNA
expression was not detected (n=6–7; Fig. 1A). In the microglia
stimulated with LPS for 24 h, the expression level of TAC4
mRNA was increased compared with the level in non-stimulated
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control; P,0.05; n=5–7; Fig. 1B). In contrast, the expression
levels of TAC1, NK1 and NK3 mRNAs were significantly
decreased to 38.2619.8%, 17.965.9% and 16.564.0% of the
corresponding levels in non-stimulated microglia (P,0.05 for
TAC1, P,0.001 for NK1 and P,0.05 for NK3; n=6–9; Fig. 1B).
No changes in TAC4 mRNA expression in microglia
following IL-1b, ATP or HK-1 treatment
In addition to LPS, other molecules such as IL-1b and ATP can
also activate microglia [20]. Therefore, we examined the effects of
IL-1b and ATP on the TAC4 mRNA expression. However,
treatment of the microglia with IL-1b or ATP for 24 h did not
significantly increase the TAC4 mRNA expression levels
(92.169.3% and 123.5613.1% expressed as percentages of the
control, respectively; n=4–9; Fig. 2). Next, we examined whether
the upregulation of TAC4 mRNA expression was induced in
autocrine and/or paracrine manners because microglia expressed
NK1 receptors of their own (Fig. 1A). However, HK-1 treatment
for 24 h had no effect on the cell number and the expression level
of TAC4 mRNA (82.167.3% expressed as a percentage of the
control; n=7–9; Fig. 2).
NF-kB and p38 MAPK inhibitors attenuate the LPS-
induced increase in the expression level of TAC4 mRNA
The TLR4 activation induced by LPS is mainly mediated by NF-
kB and MAPK pathways [21]. In addition, we previously
demonstrated that HK-1 gene expression is increased in the dorsal
spinal cord after peripheralnerve injury and blocked by a microglial
inhibitor [15]. Among the MAPKs, p38 MAPK is consistently
activated by injury in microglia [22]. Therefore, we pretreated
microglia with SC-514 and SB 203580 to block the activations of
NF-kB and p38 MAPK, respectively. The morphology of non-
stimulated microglia was characterized by bipolar or unipolar
processes and elongated cell bodies, while microglia activated by
LPS exhibited amoeboid cell bodies with retraction of extensions
(Fig. 3). In addition, LPS increased the number of microglia.
However, the morphological and numerical changes induced by
LPS treatment were greatly attenuated in the microglia pretreated
with SC-514 or SB 203580 (Fig. 3). The microglial morphology and
cell number were unaffected by SC-514 or SB 203580 alone.
Next, we investigated the involvement of the NF-kB and p38
MAPK pathways in the upregulation of TAC4 mRNA expression
in the LPS-treated microglia. SC-514 significantly inhibited the
upregulation of TAC4 mRNA expression in the LPS-treated
microglia (179.0622.8% for LPS alone and 115.968.0% for LPS
plus SC-514 expressed as percentages of the control; P,0.05;
n=6–9; Fig. 4A). SB 203580 also significantly attenuated the
upregulation of TAC4 mRNA expression (156.067.3% for LPS
alone and 130.867.2% for LPS plus SB 203580 expressed as
percentages of the control; P,0.05; n=8–10; Fig. 4B). SC-514 or
SB 203580 treatment alone had no effect on the expression levels
of TAC4 mRNA (109.3611.4% for SB 203580 and 93.1610.5%
for SC-514 expressed as percentages of the control; n=8; Fig. 4).
Pretreatment with dimethyl sulfoxide did not affect the upregula-
tion of TAC4 mRNA expression induced by LPS (94.9623.6%
expressed as a percentage of the value for LPS alone; n=4).
NF-kB and p38 MAPK inhibitors are not involved in the
LPS-induced decrease in the expression levels of TAC1,
NK1 and NK3 mRNAs
We further examined the involvement of NF-kB and p38
MAPK in the downregulation of TAC1, NK1 and NK3 mRNA
Figure 1. Tachykinin gene expressions in microglia activated by LPS. (A) Numbers of mRNA molecules in non-stimulated microglia. (B)
Expression changes in mRNAs in microglia stimulated with LPS (0.1 mg/ml) for 24 h. Data are expressed as percentages of the control microglia. n.d.,
not detected. *P,0.05 and ***P,0.001, compared with the value in non-stimulated control microglia by an unpaired t-test (n=5–9).
doi:10.1371/journal.pone.0032268.g001
Figure 2. TAC4 expression in microglia stimulated by IL-1b,
ATP and HK-1. Expression levels of TAC4 in microglia stimulated with
IL-1b (20 mg/ml), ATP (100 mM) or HK-1 (1 mM) for 24 h. Data are
expressed as percentages of the control microglia (n=4–9).
doi:10.1371/journal.pone.0032268.g002
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the downregulation of TAC1 and NK3 mRNA expressions in the
LPS-treated microglia (21.965.4% and 10.362.3% for LPS
alone, 35.2614.3% and 21.869.1% for LPS plus SB 203580
and 58.6611.9% and 19.166.7% for LPS plus SC-514 expressed
as percentages of the control, respectively; n=8–14; Fig. 5A),
although SC-514 showed a tendency to partially inhibit the
downregulation of TAC1 mRNA expression. The decreases in the
NK1 mRNA expression levels were also unaffected by SB 203580
(7.861.6% for LPS alone and 21.364.9% for LPS plus SB 203580
expressed as percentages of the control; n=6–8; Fig. 5B). On the
other hand, SC-514 partially, but significantly, inhibited the
downregulation of NK1 mRNA expression (54.369.6% for LPS
plus SC-514 expressed as a percentage of the control; P,0.05;
n=6–8; Fig. 5B).
Discussion
In this study, we found that TAC4, rather than TAC1, was the
predominant tachykinin gene expressed in microglia. Further-
more, the TAC4 mRNA expression was upregulated in microglia
upon their activation by LPS, while the TAC1 mRNA expression
was downregulated. Both the NF-kB and p38 MAPK signaling
pathways were required for the upregulation of TAC4 mRNA, but
not for the downregulation of TAC1 mRNA.
HK-1 is the predominant tachykinin in activated
microglia
In the non-stimulated condition, TAC4 mRNA was expressed
in primary cultures of microglia, as previously described for
microglial cell lines [10,15]. The expression level was much higher
than that of TAC1 mRNA. In addition, the expression of TAC4
mRNA was increased in activated microglia, while TAC1 mRNA
expression was decreased. These findings suggest that HK-1 is the
predominant endogenous NK1 receptor ligand expressed in
microglia, and that SP and HK-1 are expressed in distinct CNS
cells. In fact, SP is preferentially expressed in neurons [23] and its
mRNA expression level is much higher than that of TAC4 mRNA
expression in the nervous system [7]. On the other hand, TAC4
mRNA is expressed in the resident immunocompetent microglia,
similar to the peripheral tissues where a variety of peripheral
immune cells, including macrophages and dendritic cells, express
TAC4 mRNA [5,8–10]. TAC4 mRNA expression is uniform
throughout the whole body, and the intact brain also expresses
TAC4 mRNA at comparable amounts to peripheral tissues [7]. In
Figure 3. Morphological changes of microglia activated by LPS. Representative images of the microglial morphology are shown. Scale bar,
50 mm.
doi:10.1371/journal.pone.0032268.g003
Figure 4. Intracellular signaling pathways for TAC4 gene upregulation by LPS. Expression levels of TAC4 mRNA in microglia treated with
LPS plus SC-514 (A; an IKK-2 inhibitor) or SB 203580 (B; a p38 MAPK inhibitor). *P,0.05, **P,0.01 and ***P,0.001 by Turkey-Kramer’s multiple
comparison test (n=6–10).
doi:10.1371/journal.pone.0032268.g004
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the effects of SP and HK-1 [3–6], although both peptides activate
NK1 receptors with comparable high affinity and potency and
both NK2 and NK3 receptors with lower affinities [1,2].
Therefore, HK-1 may be distinct from SP not only in its
expressing cells, but also in its roles in the CNS.
TAC4 mRNA expression was upregulated in microglia
activated by the TLR4 agonist LPS, suggesting that HK-1 may
mediate the microglial actions on neighboring cells, such as
neurons and astrocytes. Although LPS is a component of gram-
negative bacterial cell walls, TLR4 was also reported to be
activated by various endogenous molecules, including heat shock
proteins and high mobility group box 1 protein [18,24]. We
previously showed that the expression of TAC4 mRNA was
upregulated by peripheral nerve injury in association with
microglial activation in the dorsal spinal cord. A microglial
activation inhibitor, minocycline, suppressed both the upregula-
tion of HK-1 mRNA and neuropathic pain caused by the injury
[15]. Neuropathic pain and microglial activation are also
attenuated in TLR4-deficient mice [25]. Intrathecal administra-
tion of HK-1 induces nociceptive behavior [6,26]. On the other
hand, HK-1 was reported to potentiate the antinociceptive effects
of peripheral and supraspinal opioids [27,28]. These findings
suggest that an increase in HK-1 expression can actually be
induced to mediate the microglial actions in the CNS.
Intracellular signaling pathway for the modulation of HK-
1 gene expression
The upregulation of HK-1 gene expression in the microglia
activated by LPS required NF-kB and p38 MAPK signaling
pathways. NF-kB was shown to be involved in the increase in
TAC4 gene transcription by phorbol myristate acetate in a T cell
line [29], consistent with the present data showing that NF-kB was
prerequisite for LPS-induced HK-1 mRNA upregulation in
microglia. In addition, we found that p38 MAPK, which is
involved in the transcriptional regulation of a variety of
inflammatory cytokines [30], was also required for TAC4 mRNA
upregulation. Concomitant inhibition of NF-kB and p38 MAPK
may exert synergistic inhibition as in the case of cytokine
expression [21]. However, IL-1b, which also induces inflamma-
tory mediators in microglia, did not induce HK-1 gene expression,
although both LPS and IL-1b lead to the activation of NF-kB and
p38 MAPK [31]. ATP was reported to induce p38 MAPK
activation in microglia [20,32]. These findings suggest that LPS-
induced TAC4 expression requires other additional signaling
molecules that are not recruited by IL-1b. The LPS/TLR4
signaling pathways are composed of myeloid differentiation factor
88 (MyD88)-dependent and -independent pathways [21], while
IL-1b functions through the MyD88-dependent pathway [33].
Therefore, the MyD88-independent pathway, which is unique to
TLR3 and TLR4, may also be required for the upregulation of
TAC4 mRNA expression and downregulation of TAC1 and NK
receptors. NF-kB modulates the transcription of target genes,
including type I interferons, in a cooperative manner with
interferon regulatory factor-3, a transcription factor activated
through an MyD88-independent pathway [21,34].
The modulation of HK-1 expression also seems to depend on
the cell types. In a pre-B cell line and dendritic cells, TAC4
mRNA expression was reported to be decreased by LPS [5,10].
Although the reason for the discrepancy remains unknown, TLR4
activation reportedly induces different gene expressions via similar
intracellular signaling pathways among distinct cell types, such as
dendritic cells, microglia and neurons [35]. The expression of
TAC4 mRNA in human B lymphocytes is upregulated in chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma, but down-
regulated in acute lymphoblastic leukemia [36]. In monocyte and
macrophage cell lines, both HK-1 and NK1 gene expressions are
downregulated after co-stimulation with interferon-c, IL-1b and
tumor necrosis factor-a [8].
Pathophysiological relevance of HK-1 in microglia
Activated microglia play important roles in neurodegenerative
disorders and neuroinflammation, including Alzheimer’s disease,
Parkinson’s disease and amyotrophic lateral sclerosis [16,18].
TLR-induced activation of microglia is responsible for neurotoxic
processes in these diseases [18]. On the other hand, microglia also
exert neuroprotective effects in situations such as ischemic lesions
[37]. The present data indicate that HK-1, rather than SP, may
play dominant roles in the pathological and/or restorative
situations associated with microglial activation. Therefore, further
investigation of the roles of HK-1 in connection with microglial
activation may lead to novel insights into the pathophysiology of
neurodegenerative and neuroinflammatory disorders.
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